Inebilizumab is a monoclonal antibody that can bind to CD19 and deplete CD19-expressing B cells, and has been shown as an effective and therapeutic option for the management of patients with neuromyelitis optica spectrum disorder [56,57]. The gene discussed is CD19; the disease is neuromyelitis optica.